aluates Reports

$ 0.0

Automative

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Research Report 2026

Published Date: 2026-02-26

Report Code: QYRE-Auto-24O12722

Global Duchenne Muscular Dystrophy DMD Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Research Report 2026

Code: QYRE-Auto-24O12722

Report

2026-02-26

Pages:108

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Sarepta Therapeutics

PTC Therapeutics

Italfarmaco S.p.A.

Santhera Pharmaceuticals

ReveraGen BioPharma Inc

Belief BioMed

ReveraGen BioPharma

Sperogenix

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size

The global Duchenne Muscular Dystrophy (DMD) Therapeutics market was valued at US$ 2282 million in 2025 and is anticipated to reach US$ 5021 million by 2032, at a CAGR of 12.1% from 2026 to 2032.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

The Duchenne muscular dystrophy (DMD) treatment market is primarily driven by the following factors:

I. Disease Burden and Unmet Needs

High Disability and Mortality Rates:

DMD is a progressive muscle wasting disease. Patients typically lose the ability to walk around age 10 and die from cardiopulmonary failure between the ages of 20 and 30. With approximately 300,000 cases worldwide and over 70,000 in China, the disease poses a significant social burden.

If a female carrier gives birth to a boy, there is a 50% chance that the child will inherit the disease, creating a high family genetic risk.

Limitations of Existing Treatments:

Current mainstream treatments, including corticosteroids (such as deflazacort) and topical exon-skipping drugs (such as Exondys 51), can only delay the disease, not cure it, and require long-term use with significant side effects.

There is a lack of universal treatments, which only cover specific gene mutation types (such as exon 51/53 skipping), limiting their applicable population. Improved Diagnosis Rate:

With improved medical infrastructure and urbanization, China's DMD diagnosis rate is expected to rise from approximately 30% in 2022 to over 50% in 2025, bringing more patients into the treatment-needing population.

II. R&D Progress and Pipeline Breakthroughs

Breakthroughs in Gene Therapy and Oligonucleotide Technologies:

Gene therapies, such as Sarepta's SRP-9001 (microdystrophin delivered via an AAVrh74 vector) and Faith Pharmaceuticals' BBM-D101 (engineered AAV vector), achieve long-term protein expression with a single dose. Clinical trials have shown a significant increase in the percentage of positive fibers.

Huida Gene's CRISPR-Cas12 gene editing therapy has entered clinical trials, targeting gene mutation repair.

Oligonucleotide therapies, including antisense oligonucleotides (ASOs) and next-generation peptide-coupled oligonucleotides (PPMOs), such as PepGen's PGN-EDO51 and Entrada's ENTR-601-44, enhance cellular uptake and lysosomal escape, improving efficacy and reducing dosage. Active Domestic R&D Pipeline:

Over 10 DMD drugs have entered clinical trials in China, including gene editing (such as Huida Gene's CRISPR-Cas12), AAV gene therapy (Jinwei Bio's JWK007), and mini-protein drugs (Faith Pharmaceuticals' BBM-D101). Some have received FDA orphan drug designation and are expected to be launched after 2026.

III. Policy Support and Optimized Payment Environment

Policy Support for Rare Diseases:

US: The DUX Act extends the market exclusivity period for DMD orphan drugs to 7.5 years, and the accelerated approval process shortens drug launch time by 34%.

China: DMD will be included in the second round of rare disease listings in 2024, promoting domestic R&D. Medical insurance coverage has expanded, with vamorolone included in the national medical insurance negotiations. The price of domestically produced gene therapies is expected to drop below 2 million yuan by 2026.

Improved Affordability:

North America: Commercial insurance companies (such as UnitedHealthcare) have prioritized DMD gene therapy reimbursement, with medical insurance coverage exceeding 80%. In Europe, reimbursement rates for products that pass HTA assessment exceed 80%, but product launches lag 9-15 months behind those in the US.

Asia-Pacific: Markets such as China, Japan, and South Korea are experiencing significant growth, with policies and capital jointly driving therapeutic accessibility.

The DMD therapy market is driven by disease severity, technological breakthroughs, and favorable policies. Gene editing and RNA therapies will dominate the future, but high costs and production capacity bottlenecks (such as AAV vector production) still need to be overcome. Companies need to focus on technological innovation and payment model optimization to address unmet medical needs.

This report delivers a comprehensive overview of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics. The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market comprehensively. Regional market sizes by Type, by Application, by Product Form, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Duchenne Muscular Dystrophy (DMD) Therapeutics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report

Report Metric	Details
Report Name	Duchenne Muscular Dystrophy (DMD) Therapeutics Market
Accounted market size in 2025	US$ 2282 million
Forecasted market size in 2032	US$ 5021 million
CAGR	12.1%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Exondys Emflaza Translarna Others
Segment by Product Form	Hormonal Drugs Exon Skipping Small Molecule Drugs Others
Segment by Sales Channels	Online Sales Offline Sales
Segment by Application	Hospitals Clinics Home Care
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sarepta Therapeutics, ReveraGen BioPharma, Sperogenix, ReveraGen BioPharma Inc ., Belief BioMed, PTC Therapeutics, Santhera Pharmaceuticals, Italfarmaco
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Product Form, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Duchenne Muscular Dystrophy (DMD) Therapeutics companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Duchenne Muscular Dystrophy (DMD) Therapeutics Market growing?

Ans: The Duchenne Muscular Dystrophy (DMD) Therapeutics Market witnessing a CAGR of 12.1% during the forecast period 2026-2032.

What is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market size in 2032?

Ans: The Duchenne Muscular Dystrophy (DMD) Therapeutics Market size in 2032 will be US$ 5021 million.

Who are the main players in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market report?

Ans: The main players in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market are Sarepta Therapeutics, ReveraGen BioPharma, Sperogenix, ReveraGen BioPharma Inc ., Belief BioMed, PTC Therapeutics, Santhera Pharmaceuticals, Italfarmaco

What are the Application segmentation covered in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market report?

Ans: The Applications covered in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market report are Hospitals, Clinics, Home Care

What are the Type segmentation covered in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market report?

Ans: The Types covered in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market report are Exondys, Emflaza, Translarna, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Exondys

1.2.3 Emflaza

1.2.4 Translarna

1.2.5 Others

1.3 Market by Product Form

1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Product Form: 2021 vs 2025 vs 2032

1.3.2 Hormonal Drugs

1.3.3 Exon Skipping

1.3.4 Small Molecule Drugs

1.3.5 Others

1.4 Market by Sales Channels

1.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Sales Channels: 2021 vs 2025 vs 2032

1.4.2 Online Sales

1.4.3 Offline Sales

1.5 Market by Application

1.5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Hospitals

1.5.3 Clinics

1.5.4 Home Care

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2021–2032)

2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region

2.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2021–2026)

2.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2027–2032)

2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics

2.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends

2.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers

2.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges

2.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue

3.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2021–2026)

3.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2021–2026)

3.2 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue

3.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio

3.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2025

3.5 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics Head Offices and Areas Served

3.6 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Products and Applications

3.7 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type

4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2021–2026)

4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2027–2032)

5 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application

5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2021–2026)

5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021–2032)

6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021–2026)

6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021–2032)

7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021–2026)

7.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021–2032)

8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2021–2026)

8.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021–2032)

9.2 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021–2026)

9.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2021–2032)

10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2021–2026)

10.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sarepta Therapeutics

11.1.1 Sarepta Therapeutics Company Details

11.1.2 Sarepta Therapeutics Business Overview

11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction

11.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

11.1.5 Sarepta Therapeutics Recent Development

11.2 ReveraGen BioPharma

11.2.1 ReveraGen BioPharma Company Details

11.2.2 ReveraGen BioPharma Business Overview

11.2.3 ReveraGen BioPharma Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction

11.2.4 ReveraGen BioPharma Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

11.2.5 ReveraGen BioPharma Recent Development

11.3 Sperogenix

11.3.1 Sperogenix Company Details

11.3.2 Sperogenix Business Overview

11.3.3 Sperogenix Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction

11.3.4 Sperogenix Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

11.3.5 Sperogenix Recent Development

11.4 ReveraGen BioPharma Inc .

11.4.1 ReveraGen BioPharma Inc . Company Details

11.4.2 ReveraGen BioPharma Inc . Business Overview

11.4.3 ReveraGen BioPharma Inc . Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction

11.4.4 ReveraGen BioPharma Inc . Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

11.4.5 ReveraGen BioPharma Inc . Recent Development

11.5 Belief BioMed

11.5.1 Belief BioMed Company Details

11.5.2 Belief BioMed Business Overview

11.5.3 Belief BioMed Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction

11.5.4 Belief BioMed Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

11.5.5 Belief BioMed Recent Development

11.6 PTC Therapeutics

11.6.1 PTC Therapeutics Company Details

11.6.2 PTC Therapeutics Business Overview

11.6.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction

11.6.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

11.6.5 PTC Therapeutics Recent Development

11.7 Santhera Pharmaceuticals

11.7.1 Santhera Pharmaceuticals Company Details

11.7.2 Santhera Pharmaceuticals Business Overview

11.7.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction

11.7.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

11.7.5 Santhera Pharmaceuticals Recent Development

11.8 Italfarmaco

11.8.1 Italfarmaco Company Details

11.8.2 Italfarmaco Business Overview

11.8.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Introduction

11.8.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

11.8.5 Italfarmaco Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Sarepta Therapeutics

PTC Therapeutics

Italfarmaco S.p.A.

Santhera Pharmaceuticals

ReveraGen BioPharma Inc

Belief BioMed

ReveraGen BioPharma

Sperogenix

List of Tables

Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Exondys

Table 3. Key Players of Emflaza

Table 4. Key Players of Translarna

Table 5. Key Players of Others

Table 6. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Product Form (US$ Million): 2021 vs 2025 vs 2032

Table 7. Key Players of Hormonal Drugs

Table 8. Key Players of Exon Skipping

Table 9. Key Players of Small Molecule Drugs

Table 10. Key Players of Others

Table 11. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Sales Channels (US$ Million): 2021 vs 2025 vs 2032

Table 12. Key Players of Online Sales

Table 13. Key Players of Offline Sales

Table 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million), 2021–2026

Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2021–2026)

Table 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (US$ Million), 2027–2032

Table 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2027–2032)

Table 20. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends

Table 21. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers

Table 22. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges

Table 23. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints

Table 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (US$ Million), 2021–2026

Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players (2021–2026)

Table 26. Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Tier (Tier 1, Tier 2, and Tier 3), based on Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, 2025

Table 27. Ranking of Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Companies by Revenue (US$ Million) in 2025

Table 28. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (CR5 and HHI), 2021–2026

Table 29. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Headquarters and Area Served

Table 30. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Products and Applications

Table 31. Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics, Date of General Availability (GA)

Table 32. Mergers and Acquisitions, Expansion Plans

Table 33. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type (US$ Million), 2021–2026

Table 34. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2021–2026)

Table 35. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (US$ Million), 2027–2032

Table 36. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2027–2032)

Table 37. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (US$ Million), 2021–2026

Table 38. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2021–2026)

Table 39. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (US$ Million), 2027–2032

Table 40. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2027–2032)

Table 41. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 43. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 44. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 46. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 47. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 48. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million), 2021–2026

Table 49. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (US$ Million), 2027–2032

Table 50. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 51. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 52. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 53. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 54. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 55. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 56. Sarepta Therapeutics Company Details

Table 57. Sarepta Therapeutics Business Overview

Table 58. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product

Table 59. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (US$ Million), 2021–2026

Table 60. Sarepta Therapeutics Recent Development

Table 61. ReveraGen BioPharma Company Details

Table 62. ReveraGen BioPharma Business Overview

Table 63. ReveraGen BioPharma Duchenne Muscular Dystrophy (DMD) Therapeutics Product

Table 64. ReveraGen BioPharma Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (US$ Million), 2021–2026

Table 65. ReveraGen BioPharma Recent Development

Table 66. Sperogenix Company Details

Table 67. Sperogenix Business Overview

Table 68. Sperogenix Duchenne Muscular Dystrophy (DMD) Therapeutics Product

Table 69. Sperogenix Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (US$ Million), 2021–2026

Table 70. Sperogenix Recent Development

Table 71. ReveraGen BioPharma Inc . Company Details

Table 72. ReveraGen BioPharma Inc . Business Overview

Table 73. ReveraGen BioPharma Inc . Duchenne Muscular Dystrophy (DMD) Therapeutics Product

Table 74. ReveraGen BioPharma Inc . Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (US$ Million), 2021–2026

Table 75. ReveraGen BioPharma Inc . Recent Development

Table 76. Belief BioMed Company Details

Table 77. Belief BioMed Business Overview

Table 78. Belief BioMed Duchenne Muscular Dystrophy (DMD) Therapeutics Product

Table 79. Belief BioMed Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (US$ Million), 2021–2026

Table 80. Belief BioMed Recent Development

Table 81. PTC Therapeutics Company Details

Table 82. PTC Therapeutics Business Overview

Table 83. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product

Table 84. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (US$ Million), 2021–2026

Table 85. PTC Therapeutics Recent Development

Table 86. Santhera Pharmaceuticals Company Details

Table 87. Santhera Pharmaceuticals Business Overview

Table 88. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product

Table 89. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (US$ Million), 2021–2026

Table 90. Santhera Pharmaceuticals Recent Development

Table 91. Italfarmaco Company Details

Table 92. Italfarmaco Business Overview

Table 93. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product

Table 94. Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (US$ Million), 2021–2026

Table 95. Italfarmaco Recent Development

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

Table 99. Authors List of This Report

List of Figures

Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Picture

Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Type: 2025 vs 2032

Figure 4. Exondys Features

Figure 5. Emflaza Features

Figure 6. Translarna Features

Figure 7. Others Features

Figure 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Product Form (US$ Million), 2021–2032

Figure 9. Hormonal Drugs Features

Figure 10. Exon Skipping Features

Figure 11. Small Molecule Drugs Features

Figure 12. Others Features

Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Comparison by Sales Channels (US$ Million), 2021–2032

Figure 14. Online Sales Features

Figure 15. Offline Sales Features

Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application (US$ Million), 2021–2032

Figure 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Application: 2025 vs 2032

Figure 18. Hospitals Case Studies

Figure 19. Clinics Case Studies

Figure 20. Home Care Case Studies

Figure 21. Duchenne Muscular Dystrophy (DMD) Therapeutics Report Years Considered

Figure 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 24. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2025 vs 2032

Figure 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Players in 2025

Figure 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 27. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue in 2025

Figure 28. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021–2032)

Figure 30. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021–2032)

Figure 34. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Ireland Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2021–2032)

Figure 42. China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Australia & New Zealand Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021–2032)

Figure 50. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 52. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Country (2021–2032)

Figure 54. Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 55. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 56. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 57. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

Figure 58. ReveraGen BioPharma Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

Figure 59. Sperogenix Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

Figure 60. ReveraGen BioPharma Inc . Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

Figure 61. Belief BioMed Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

Figure 62. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

Figure 63. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

Figure 64. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2021–2026)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Duchenne Muscular Dystrophy Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030

Myotonic Dystrophy Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Myotonic Dystrophy Treatment Market Research Report 2025

Global Myotonic Dystrophy Drug Market Research Report 2024

Myotonic Dystrophy Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Spinal Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Duchenne Muscular Dystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Spinal Muscular Atrophy SMA Treatment Market Research Report 2024

Global Amyotrophic Lateral Sclerosis Therapeutics Market Insights Forecast to 2030

Myotonic Muscular Dystrophy DMD Treatments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Sarcopenia Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hunter Syndrome Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Amyotrophic Lateral Sclerosis ALS Treatment Market Insights Forecast to 2030

Global Myasthenia Gravis Therapies Market Research Report 2024

Myasthenia Gravis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cone rod Dystrophy Treatment Market Research Report 2025

Spinal Muscular Atrophy SMA Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

MSD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Amyotrophic Lateral Sclerosis ALS Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions